- Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007)Huang, Jing; Song, Yan; Kou, Xiaoge; Tan, Zhenbo; Zhang, Shu; Sun, Meili; Zhou, Jin; Fan, Min; Zhang, Ming; Song, Yongxiang; Li, Suyi; Yuan, Yuan; Zhuang, Wu; Zhang, Jingdong; Zhang, Li; Jiang, Hao; Gu, Kangsheng; Ye, Huangyang; Wang, Qingyu; Zhu, JunAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (mESCC): Safety run-in results from the phase III LEAP-014 studySun, J-M.; Lin, C-Y.; Rojas, C.; Rivera, F.; Kwong, D.; Chen, M-H.; Zhang, Y.; Yamamoto, S.; Yu, L.; Shah, S.; Bhagia, P.; Shen, L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Penpulimab plus chemotherapy with or without anlotinib as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ANSWER): A randomized, two-arm, clinical trial in progress.Wang, Wei; Lin, Shuimiao; Wang, Rong; Wu, DehuaGenitourinary Cancers Symposium, San Francisco, CA, 2023-01-19 To 2023-01-21.
会议论文
First-line serplulimab versus placebo in combination with chemotherapy in PD-L1-positive oesophageal squamous cell carcinoma (ASTRUM-007): A randomised, double-blind, multicentre phase III study
1被引16阅读
